Red cell distribution width/platelet ratio estimates the 3-year risk of decompensation in Metabolic Dysfunction-Associated Steatotic Liver Disease-induced cirrhosis

Table 4 Non-invasive tools for liver disease severity assessment of the study population (baseline)

Variables (mean ± SD)	Healthy subjects (n = 40)	cACLD patients (n = 150)	P value
LSM (kPa)	NA	19.67 ± 3.39	/
APRI	NA	1.75 ± 0.28	/
FIB-4	NA	3.11 ± 1.78	/
ALBI	NA	-2.378 ± 0.63	/
ALBI-FIB-4	NA	1.44 ± 0.99	/
Child-Pugh	NA	6.24 ± 1.23	/
MELD	NA	7.74 ± 2.69	/
RDW (fL)/PLT ratio	0.17 ± 0.03	0.458 ± 0.27	/

LSM: Liver stiffness measurement; APRI: Aspartate aminotransferase/platelet count ratio index; MELD: Model for End-stage Liver Disease; FIB-4: Fibrosis-4; NA: Not-assessed (or not-appliable); cACLD: Compensated advanced chronic liver disease.